{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:43:32Z","timestamp":1791229412268,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11239-018-1786-z","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T12:01:24Z","timestamp":1543838484000},"page":"233-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1007","volume":"47","author":[{"given":"Babikir","family":"Kheiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Haykal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakr","family":"Swaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Bachuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al Qasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"1786_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0140-6736(07)61448-2","volume":"370","author":"PM Rothwell","year":"2007","unstructured":"Rothwell PM, Giles MF, Chandratheva A et al (2007) Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 370:1432\u20131442","journal-title":"Lancet"},{"key":"1786_CR2","doi-asserted-by":"crossref","unstructured":"Kernan WN, Ovbiagele B, Black HR et al (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","DOI":"10.1161\/STROKEAHA.115.008661"},{"key":"1786_CR3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","unstructured":"International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569\u20131581","journal-title":"Lancet"},{"key":"1786_CR4","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","volume":"349","author":"CAST (Chinese Acute Stroke Trial) Collaborative Group","year":"1997","unstructured":"CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641\u20131649","journal-title":"Lancet"},{"key":"1786_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71\u201386","journal-title":"BMJ"},{"key":"1786_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","volume":"388","author":"PM Rothwell","year":"2016","unstructured":"Rothwell PM, Algra A, Chen Z et al (2016) Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388:365\u2013375","journal-title":"Lancet"},{"key":"1786_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering committee","year":"1996","unstructured":"CAPRIE Steering committee (1996) A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"1786_CR8","unstructured":"Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines"},{"key":"1786_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1996","unstructured":"Diener HC, Cunha L, Forbes C et al (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1\u201313","journal-title":"J Neurol Sci"},{"key":"1786_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","volume":"367","author":"The ESPRIT Study Group","year":"2006","unstructured":"The ESPRIT Study Group (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665\u20131673","journal-title":"Lancet"},{"key":"1786_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/STROKEAHA.111.637686","volume":"43","author":"CM Geeganage","year":"2012","unstructured":"Geeganage CM, Diener H-C, Algra A et al (2012) Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 43:1058\u20131066","journal-title":"Stroke"},{"key":"1786_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2013.06.025","volume":"332","author":"X Li","year":"2013","unstructured":"Li X, Zhou G, Zhou X, Zhou S (2013) The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci 332:92\u201396","journal-title":"J Neurol Sci"},{"key":"1786_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/ene.12982","volume":"23","author":"F Ge","year":"2016","unstructured":"Ge F, Lin H, Liu Y et al (2016) Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol 23:1051\u20131057","journal-title":"Eur J Neurol"},{"key":"1786_CR14","doi-asserted-by":"publisher","first-page":"e009013","DOI":"10.1136\/bmjopen-2015-009013","volume":"6","author":"PP Niu","year":"2016","unstructured":"Niu PP, Guo ZN, Jin H et al (2016) Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ Open 6:e009013","journal-title":"BMJ Open"},{"key":"1786_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","volume":"359","author":"RL Sacco","year":"2008","unstructured":"Sacco RL, Diener H-C, Yusuf S et al (2008) Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359:1238\u20131251","journal-title":"N Engl J Med"},{"key":"1786_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(17)32849-0","volume":"391","author":"PM Bath","year":"2018","unstructured":"Bath PM, Woodhouse LJ, Appleton JP et al (2018) Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet 391:850\u2013859","journal-title":"Lancet"},{"key":"1786_CR17","doi-asserted-by":"publisher","first-page":"e2852","DOI":"10.1371\/journal.pone.0002852","volume":"3","author":"N Sprigg","year":"2008","unstructured":"Sprigg N, Gray LJ, England T et al (2008) A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS ONE 3:e2852","journal-title":"PLoS ONE"},{"key":"1786_CR18","doi-asserted-by":"crossref","unstructured":"Powers WJ, Rabinstein AA, Ackerson T et al (2018) 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","DOI":"10.1161\/STROKEAHA.119.026917"},{"key":"1786_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1\u20139","journal-title":"Syst Rev"},{"key":"1786_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/ijs.12003","volume":"9","author":"AY Lau","year":"2014","unstructured":"Lau AY, Zhao Y, Chen C et al (2014) Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. Int J Stroke 9:127\u2013132","journal-title":"Int J Stroke"},{"key":"1786_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1159\/000236915","volume":"28","author":"C Bal Dit Sollier","year":"2009","unstructured":"Bal Dit Sollier C, Crassard I, Simoneau G et al (2009) Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 28:505\u2013513","journal-title":"Cerebrovasc Dis"},{"key":"1786_CR22","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","volume":"111","author":"HS Markus","year":"2005","unstructured":"Markus HS, Droste DW, Kaps M et al (2005) Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 111:2233\u20132240","journal-title":"Circulation"},{"key":"1786_CR23","doi-asserted-by":"publisher","first-page":"e5497","DOI":"10.1097\/MD.0000000000005497","volume":"96","author":"F-T Zuo","year":"2017","unstructured":"Zuo F-T, Liu H, Wu H-J et al (2017) The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: a randomized and controlled trail. Med 96:e5497","journal-title":"Med"},{"key":"1786_CR24","doi-asserted-by":"crossref","first-page":"17725","DOI":"10.18632\/oncotarget.24877","volume":"9","author":"X Yi","year":"2018","unstructured":"Yi X, Lin J, Zhou J et al (2018) The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke. Oncotarget 9:17725\u201317734","journal-title":"Oncotarget"},{"key":"1786_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.clinthera.2008.02.006","volume":"30","author":"VL Serebruany","year":"2008","unstructured":"Serebruany VL, Malinin AI, Pokov AN, Hanley DF (2008) Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b. Clin Ther 30:249\u2013259","journal-title":"Clin Ther"},{"key":"1786_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.114.014791","volume":"132","author":"Y Wang","year":"2015","unstructured":"Wang Y, Pan Y, Zhao X et al (2015) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation 132:40\u201346","journal-title":"Circulation"},{"key":"1786_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1474-4422(10)70060-0","volume":"9","author":"KSL Wong","year":"2010","unstructured":"Wong KSL, Chen C, Fu J et al (2010) Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 9:489\u2013497","journal-title":"Lancet Neurol"},{"key":"1786_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1747-4949.2010.00535.x","volume":"6","author":"GJ Hankey","year":"2011","unstructured":"Hankey GJ, Johnston SC, Easton JD et al (2011) Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke 6:3\u20139","journal-title":"Int J Stroke"},{"key":"1786_CR29","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","volume":"6","author":"J Kennedy","year":"2007","unstructured":"Kennedy J, Hill MD, Ryckborst KJ et al (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 6:961\u2013969","journal-title":"Lancet Neurol"},{"key":"1786_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","volume":"364","author":"H-C Diener","year":"2004","unstructured":"Diener H-C, Bogousslavsky J, Brass LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331\u2013337","journal-title":"Lancet"},{"key":"1786_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jocn.2014.05.038","volume":"22","author":"F He","year":"2015","unstructured":"He F, Xia C, Zhang JH et al (2015) Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke. J Clin Neurosci 22:83\u201386","journal-title":"J Clin Neurosci"},{"key":"1786_CR32","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/STROKEAHA.115.012293","volume":"47","author":"KS Hong","year":"2016","unstructured":"Hong KS, Lee SH, Kim EG et al (2016) recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone. Stroke 47:2323\u20132330","journal-title":"Stroke"},{"key":"1786_CR33","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1161\/01.STR.0000181081.09262.e1","volume":"36","author":"VL Serebruany","year":"2005","unstructured":"Serebruany VL, Malinin AI, Ziai W et al (2005) Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: For the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke 36:2289\u20132292","journal-title":"Stroke"},{"key":"1786_CR34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1056\/NEJMoa1204133","volume":"367","author":"O Benavente","year":"2012","unstructured":"Benavente O, Hart R, McClure L et al (2012) Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367:817\u2013825","journal-title":"N Engl J Med"},{"key":"1786_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3988\/jcn.2015.11.1.57","volume":"11","author":"X Yi","year":"2015","unstructured":"Yi X, Chi W, Wang C et al (2015) Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients. J Clin Neurol 11:57\u201365","journal-title":"J Clin Neurol"},{"key":"1786_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410","author":"SC Johnston","year":"2018","unstructured":"Johnston SC, Easton JD, Farrant M et al (2018) Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1800410","journal-title":"N Engl J Med"},{"key":"1786_CR37","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706\u20131717","journal-title":"N Engl J Med"},{"key":"1786_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/svn-2016-000008","volume":"1","author":"D Wang","year":"2016","unstructured":"Wang D, Gui L, Dong Y et al (2016) Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke Vasc Neurol 1:29\u201336","journal-title":"Stroke Vasc Neurol"},{"key":"1786_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang Y, Zhao X et al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11\u201319","journal-title":"N Engl J Med"},{"key":"1786_CR40","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.01.022","volume":"23","author":"X Yi","year":"2014","unstructured":"Yi X, Lin J, Wang C et al (2014) A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis 23:1975\u20131981","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1786_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/1076029614551823","volume":"21","author":"C Wang","year":"2015","unstructured":"Wang C, Yi X, Zhang B et al (2015) Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. Clin Appl Thromb Hemost 21:453\u2013461","journal-title":"Clin Appl Thromb Hemost"},{"key":"1786_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/svn-2017-000072","volume":"2","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Yang W, Tan Z et al (2017) Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke Vasc Neurol 2:118\u2013123","journal-title":"Stroke Vasc Neurol"},{"key":"1786_CR43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/clc.22570","volume":"39","author":"E Anstey","year":"2016","unstructured":"Anstey E, Li S, Thomas L et al (2016) Race and sex differences in management and outcomes of patients after ST-elevation and non-ST-elevation myocardial infarct: results from the NCDR. Clin Cardiol 39:585\u2013595","journal-title":"Clin Cardiol"},{"key":"1786_CR44","doi-asserted-by":"crossref","first-page":"e009564","DOI":"10.1161\/JAHA.118.009564","volume":"7","author":"AA Schmaier","year":"2018","unstructured":"Schmaier AA, Bhatt DL (2018) Are patients getting their aspirin\u2019s worth in ischemic stroke? J Am Hear Assoc 7:e009564","journal-title":"J Am Hear Assoc"},{"key":"1786_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.116.025198","volume":"135","author":"T Simon","year":"2017","unstructured":"Simon T, Danchin N (2017) Clinical impact of pharmacogenomics of clopidogrel in stroke. Circulation 135:34\u201337","journal-title":"Circulation"},{"key":"1786_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","volume":"135","author":"Y Pan","year":"2017","unstructured":"Pan Y, Chen W, Xu Y et al (2017) genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 135:21\u201333","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1786-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:37:46Z","timestamp":1662550666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1786-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1786-z","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"3 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Mustafa Hassan has received a research grant from Abbott. Dr. Mohammed Al Qasmi is on speaker bureau for Genentech. Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today\u2019s Intervention), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim,\u00a0Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald\u2019s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk,\u00a0PLx Pharma, Takeda. The remaining authors report no relationships that could be construed as a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}